• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性免疫性多神经病治疗中治疗性血液成分单采的关键方法。

A critical approach to therapeutic apheresis in the management of inflammatory dysimmune polyneuropathies.

作者信息

Valbonesi M, Montani F, Mosconi L, Zerbi D, Beltramelli A, Florio G

出版信息

Haematologia (Budap). 1985;18(1):33-43.

PMID:3996945
Abstract

Data concerning 37 patients with inflammatory dysimmune polyneuropathy treated by discontinuous flow centrifugation, membrane plasma separation and cascade filtration are presented. Plasmapheresis was combined with immunosuppressants in patients with chronic or relapsing neuropathy (8 patients), cryoglobulinemic (6 patients) and paraneoplastic disease (2 patients), whereas 21 patients with acute Guillain-Barré syndrome (GBS) underwent exclusively plasmapheresis. Most patients were treated during the onset or progression of their disease and excellent or satisfactory clinical results were obtained in 18 patients with GBS, 6 with cryoglobulinemia, 2 with paraneoplastic disease and 4 with chronic relapsing polyneuropathy. Prior to therapy, 34 patients had high levels of immune complexes (CIC); this level was clearly reduced by plasmapheresis and clinical results correlated well with this removal. 3 patients with chronic dysimmune polyneuropathy, without any evidence of CIC, were completely unaffected by treatment. The possible role of CIC in demyelinating polyneuropathies is discussed on the basis of information given by cascade filtration treatment of 7 patients.

摘要

本文介绍了37例采用间断流动离心、膜血浆分离和级联过滤治疗的炎性免疫性多神经病患者的数据。对于慢性或复发性神经病患者(8例)、冷球蛋白血症患者(6例)和副肿瘤性疾病患者(2例),血浆置换联合免疫抑制剂治疗;而21例急性吉兰-巴雷综合征(GBS)患者仅接受血浆置换治疗。大多数患者在疾病发作或进展期接受治疗,18例GBS患者、6例冷球蛋白血症患者、2例副肿瘤性疾病患者和4例慢性复发性多神经病患者获得了优异或满意的临床结果。治疗前,34例患者免疫复合物(CIC)水平较高;血浆置换明显降低了该水平,临床结果与这种清除效果密切相关。3例慢性免疫性多神经病患者无CIC证据,治疗对其完全无效。基于7例患者的级联过滤治疗信息,讨论了CIC在脱髓鞘性多神经病中的可能作用。

相似文献

1
A critical approach to therapeutic apheresis in the management of inflammatory dysimmune polyneuropathies.炎症性免疫性多神经病治疗中治疗性血液成分单采的关键方法。
Haematologia (Budap). 1985;18(1):33-43.
2
Long-term plasmapheresis therapy is effective and safe in children with chronic relapsing dysimmune polyneuropathy.
Rev Neurol (Paris). 1990;146(2):123-7.
3
Plasmapheresis for neurological disorders.用于神经系统疾病的血浆置换术。
Expert Rev Neurother. 2009 Sep;9(9):1331-9. doi: 10.1586/ern.09.81.
4
Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology. 1996 Sep;47(3):840-3.
5
[Results of treatment with plasmapheresis in myasthenic crisis and severe polyneuropathy].[血浆置换治疗重症肌无力危象和严重多发性神经病的结果]
Pol Arch Med Wewn. 1991 Dec;86(6):416-9.
6
Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia.
Haematologia (Budap). 1984;17(3):341-51.
7
[Axonal involvement in dysimmune neuropathies].[轴突在免疫性神经病中的受累情况]
Rev Neurol (Paris). 2007 Sep;163 Spec No 1:3S5-11.
8
The role of therapeutic apheresis in acute, relapsing, and chronic inflammatory demyelinating polyneuropathy.
Prog Clin Biol Res. 1982;106:205-17.
9
[Recent aspects of acute and chronic inflammatory polyneuropathies: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy].[急性和慢性炎性多发性神经病的近期研究进展:吉兰-巴雷综合征和慢性炎性脱髓鞘性多发性神经病]
Rev Neurol. 2002;35(3):269-76.
10
Treatment of immune-mediated, dysimmune neuropathies.免疫介导性、免疫失调性神经病的治疗。
Acta Neurol Scand. 2005 Aug;112(2):115-25. doi: 10.1111/j.1600-0404.2005.00448.x.

引用本文的文献

1
A review of the therapy of paraneoplastic neurologic syndromes.副肿瘤性神经系统综合征的治疗综述。
J Neurooncol. 1999 Jan;41(2):181-94. doi: 10.1023/a:1006133102928.
2
Immunoadsorption therapy for paraneoplastic syndromes.
J Neurooncol. 1998 Nov;40(2):131-6. doi: 10.1023/a:1006136219490.